454 results on '"Green, Justin A."'
Search Results
2. Phase 3 Safety and Efficacy of AZD1222 (ChAdOx1 nCoV-19) Covid-19 Vaccine
3. Effect of primaquine dose on the risk of recurrence in patients with uncomplicated Plasmodium vivax: a systematic review and individual patient data meta-analysis
4. Primaquine dose and the risk of haemolysis in patients with uncomplicated Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
5. Lineage-informative microhaplotypes for recurrence classification and spatio-temporal surveillance of Plasmodium vivax malaria parasites
6. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
7. Tafenoquine co-administered with dihydroartemisinin–piperaquine for the radical cure of Plasmodium vivax malaria (INSPECTOR): a randomised, placebo-controlled, efficacy and safety study
8. Methaemoglobin as a surrogate marker of primaquine antihypnozoite activity in Plasmodium vivax malaria: a systematic review and individual patient data meta-analysis
9. Cutaneous Ulcerations as the Presenting Sign of Acute Aortic Occlusion
10. A molecular barcode and web-based data analysis tool to identify imported Plasmodium vivax malaria
11. Reviewing the use of imiquimod for molluscum contagiosum
12. Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'
13. Author response: Response to comment on 'The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis'
14. 12 The Oxford - AstraZeneca COVID-19 vaccine: Breakthrough science and collaborative partnership
15. Durability of protection and immunogenicity of AZD1222 (ChAdOx1 nCoV-19) COVID-19 vaccine over 6 months
16. Seasonal human coronavirus humoral responses in AZD1222 (ChaAdOx1 nCoV-19) COVID-19 vaccinated adults reveal limited cross-immunity.
17. Immunogenicity and safety of AZD2816, a beta (B.1.351) variant COVID-19 vaccine, and AZD1222 (ChAdOx1 nCoV-19) as third-dose boosters for previously vaccinated adults: a multicentre, randomised, partly double-blinded, phase 2/3 non-inferiority immunobridging study in the UK and Poland
18. Medical image learning from a few/few training samples: Melanoma segmentation study
19. Provider and household costs of Plasmodium vivax malaria episodes: a multicountry comparative analysis of primary trial data/Cout des episodes de paludisme a Plasmodium vivax pour les menages et les prestataires: une analyse comparative multipays de donnees d'essais primaries/Costos del proveedor y del hogar de los episodios de malaria por Plasmodium vivax: un analisis comparativo multinacional de los datos del ensayo primario
20. Precision Landing Performance and Technology Assessments of a Human-Scale Lunar Lander Using a Generalized Simulation Framework
21. Precision Landing Performance and Technology Assessments of a Human-Scale Lunar Lander Using a Generalized Simulation Framework
22. Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers
23. Saccharomyces cerevisiae derived postbiotic alters gut microbiome metabolism in the human distal colon resulting in immunomodulatory potential in vitro.
24. Evaluating a Planning Product for Active Cyberdefense and Cyberdeception
25. Erythema Ab Igne Associated With Cannabinoid Hyperemesis Syndrome
26. The role of matrix metalloproteinases in the immunopathology of cerebral tuberculosis
27. Justin Green's Show & tell comics.
28. Injectable Antioxidant and Oxygen-Releasing Lignin Composites to Promote Wound Healing
29. Lineage-informative microhaplotypes for spatio-temporal surveillance of Plasmodium vivax malaria parasites
30. Pharmacogenetic assessment of tafenoquine efficacy in patients with Plasmodium vivax malaria
31. GREEN, JUSTIN
32. AeroFusion: Data Fusion and Uncertainty Quantification for Entry Vehicles
33. Robust humoral and cellular recall responses to AZD1222 attenuate breakthrough SARS-CoV-2 infection compared to unvaccinated
34. Coexistent Cutaneous Cryptococcosis and Kaposi¹s Sarcoma in AIDS
35. The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis
36. 1953. Immune responses, viral shedding, and COVID-19 symptom burden from breakthrough SARS-CoV-2 infection in a 2:1 randomized, double-blind, placebo-controlled Phase 3 study of AZD1222 (ChAdOx1 nCoV-19) vaccination
37. Estimation of the Antirelapse Efficacy of Tafenoquine, Using Plasmodium vivax Genotyping
38. One year safety and immunogenicity of AZD1222 (ChAdOx1 nCoV-19): Final analysis of a randomized, placebo-controlled phase 1/2 trial in Japan
39. Behçet disease
40. Aphthous stomatitis
41. List of Contributors
42. Author response: The clinical pharmacology of tafenoquine in the radical cure of Plasmodium vivax malaria: An individual patient data meta-analysis
43. A pharmacometrics approach to assess the feasibility of capillary microsampling to replace venous sampling in clinical studies: Tafenoquine case study
44. Tolerability and immunogenicity of an intranasally-administered adenovirus-vectored COVID-19 vaccine: An open-label partially-randomised ascending dose phase I trial
45. ADEPT Sounding Rocket One Flight Test Overview
46. Flight Mechanics Modeling and Post-Flight Analysis of ADEPT SR-1
47. Subsonic Dynamic Testing of a Subscale ADEPT Entry Vehicle
48. Finding your voice: do trainees really know how to speak up?
49. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double-blind, randomised, phase 2b dose-selection study
50. Panel: Comics and Autobiography : May 19, 2012Moderated by Deborah Nelson
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.